(19)
(11) EP 2 436 696 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.12.2017 Bulletin 2017/50

(45) Mention of the grant of the patent:
07.06.2017 Bulletin 2017/23

(21) Application number: 11185486.5

(22) Date of filing: 07.01.2008
(51) International Patent Classification (IPC): 
C07K 16/18(2006.01)
A61P 25/28(2006.01)
A61K 39/395(2006.01)

(54)

Anti-beta-amyloid antibody and uses thereof

Anti-Beta-Amyloid-Antikörper und Verwendung davon

Anticorps anti-amyloide et son utilisation


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 05.01.2007 US 878831 P
11.06.2007 US 934291 P
05.01.2007 EP 07000211
17.10.2007 EP 07020341

(43) Date of publication of application:
04.04.2012 Bulletin 2012/14

(60) Divisional application:
17169749.3 / 3239174

(62) Application number of the earlier application in accordance with Art. 76 EPC:
08700998.1 / 2099826

(73) Proprietor: University of Zurich
8006 Zurich (CH)

(72) Inventors:
  • Nitsch, Roger, Prof. Dr.
    8126 Zumikon (CH)
  • Hock, Christoph, Prof.
    8703 Erlenbach (CH)
  • Esslinger, Christoph, Dr.
    8032 Zurich (CH)
  • Knobloch, Marlen
    1131 Tolochenaz (CH)
  • Tissot, Kathrin
    82061 Neuried (DE)
  • Grimm, Jan, Dr.
    8600 Düebendorf (CH)

(74) Representative: Steinecke, Peter 
Müller Fottner Steinecke Rechtsanwalts- und Patentanwaltspartnerschaft mbB Römerstrasse 16 b
52428 Jülich
52428 Jülich (DE)


(56) References cited: : 
EP-A- 1 172 378
WO-A-2006/103116
WO-A-2005/018424
   
  • GEYLIS V ET AL: "Human monoclonal antibodies against amyloid-beta from healthy adults", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 26, no. 5, May 2005 (2005-05), pages 597-606, XP004748495, ISSN: 0197-4580
  • MASTERS C L ET AL: "AMYLOID PLAQUE CORE PROTEIN IN ALZHEIMER DISEASE AND DOWN SYNDROME", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC; US, vol. 82, no. 12, 1 June 1985 (1985-06-01), pages 4245-4249, XP009012931, ISSN: 0027-8424, DOI: 10.1073/PNAS.82.12.4245
  • GEYLIS ET AL: "Immunotherapy of Alzheimer's disease (AD): From murine models to anti-amyloid beta (Abeta) human monoclonal antibodies", AUTOIMMUNITY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 5, no. 1, January 2006 (2006-01), pages 33-39, XP005203566, ISSN: 1568-9972
  • DU Y ET AL: "Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity", BRAIN, OXFORD UNIVERSITY PRESS, OXFORD, GB, vol. 126, no. 9, September 2003 (2003-09), pages 1935-1939, XP002360367, ISSN: 0006-8950
  • FRÉDÉRIQUE BARD ET AL: "Epitope and isotype specificities of antibodies to [beta]-amyloid peptide for protection against Alzheimer's disease-like neuropathology", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC; US, vol. 100, no. 4, 18 February 2003 (2003-02-18), pages 2023-2028, XP002630662, ISSN: 0027-8424, DOI: 10.1073/PNAS.0436286100
  • LEE E B ET AL: "Targeting Amyloid-beta Peptide (Abeta) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Abeta Precursor Protein (APP) Transgenic Mice", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 281, no. 7, 17 February 2006 (2006-02-17), pages 4292-4299, XP003013340, ISSN: 0021-9258, DOI: 10.1074/JBC.M511018200
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).